Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Although some of these infections can be treated easily, others - like the superbug MRSA and other drug-resistant bugs - can be fatal or affect patients’ health very seriously, taking several months of costly hospital care and medication to beat. A survey by the European Centre for Diseases Prevention and Control (ECDC) found that on any given day, one in 18 patients in European hospitals has at least one hospital-acquired infection - amounting to around 3.2 million patients per year. “Healthcare-associated infections pose a major public health problem and a threat to European patients,” said Marc Sprenger, director of the Stockholm-based ECDC. He said many of these infections could be prevented by well thought-out, sustained and multi-pronged prevention and control programs and he urged hospitals to step up the fight. “Such programs, as well as prudent use of antibiotics, will help all actors involved to protect the patients of European hospitals,” he said in a statement. The ECDC warned last year that doctors are increasingly having to turn to last-ditch antibiotics due to growing drug-resistant superbug infections in Europe - many of them acquired in hospitals. The latest survey, which covered 1,000 hospitals in 30 European countries, found the highest rates of hospital-acquired infections were among patients admitted to intensive care units, where 19.5 percent of patients had at least one bug they had picked up from the hospital. The most common types of infection are respiratory tract infections such as pneumonia and infections of the bloodstream. These are often caused by Klebsiella pneumonia and E. coli bacteria, both of which have shown an ability to develop resistance to some of the most powerful antibiotics. Among a total 15,000 reported healthcare-associated infections, surgical site infections and urinary tract infections are also common. Many of the infections are also found to be drug-resistant “superbugs”, the survey showed. Among all infections with Staphylococcus aureus bacteria in which full testing was carried out, more than 40 percent were reported as resistant to methicillin - in other words they were MRSA infections, the ECDC said. Worldwide, MRSA infects an estimated 53 million people annually and costs more than $20 billion a year to treat. It kills around 20,000 people a year in the United States and a similar number in Europe. EU health and consumer affairs commissioner Paola Testori Coggi said the findings of the European survey were “worrying” and urged health authorities to do more to protect patients in hospital and to step up the fight against antibiotic resistance. Drug resistance is driven by the misuse and overuse of antibiotics, which encourages bacteria to develop new ways of overcoming them. Experts say hospitals are often guilty of overusing antibiotics, giving them as “blanket” treatments before full testing has established which drugs are really needed.

Ex Output:
Three million Europeans catch infections in hospital annually.


Ex Input:
This is a sentence spoken by Trump, not a piece of modernist stream-of-consciousness pastiche. pic.twitter.com/vfhdKzg9Uy — Stig Abell (@StigAbell) August 9, 2016  On 19 July 2016, Republican presidential candidate Donald Trump appeared at Sun City’s Magnolia Hall in South Carolina to deliver a noontime speech. The event was an otherwise unremarkable campaign stop, save for one portion of Trump’s speech (transcribed below) in which he apparently started out attempting to criticize the nuclear deal that the Obama administration negotiated with Iran but veered into a minute-and-a-half long sentence that spanned his uncle’s academic qualifications, his own education, Democrats’ denying Republicans’ credentials, the power of nuclear technology, the number of American prisoners freed by Iran in conjunction with the nuclear deal, and the adeptness of “Persian” negotiators (particularly women), before circling back to how the Iranians “killed us” in the nuclear deal:   “Look, having nuclear — my uncle was a great professor and scientist and engineer, Dr. John Trump at MIT; good genes, very good genes, OK, very smart, the Wharton School of Finance, very good, very smart — you know, if you’re a conservative Republican, if I were a liberal, if, like, OK, if I ran as a liberal Democrat, they would say I’m one of the smartest people anywhere in the world — it’s true! — but when you’re a conservative Republican they try — oh, do they do a number — that’s why I always start off: Went to Wharton, was a good student, went there, went there, did this, built a fortune — you know I have to give my like credentials all the time, because we’re a little disadvantaged — but you look at the nuclear deal, the thing that really bothers me — it would have been so easy, and it’s not as important as these lives are — nuclear is so powerful; my uncle explained that to me many, many years ago, the power and that was 35 years ago; he would explain the power of what’s going to happen and he was right, who would have thought? — but when you look at what’s going on with the four prisoners — now it used to be three, now it’s four — but when it was three and even now, I would have said it’s all in the messenger; fellas, and it is fellas because, you know, they don’t, they haven’t figured that the women are smarter right now than the men, so, you know, it’s gonna take them about another 150 years — but the Persians are great negotiators, the Iranians are great negotiators, so, and they, they just killed, they just killed us, this is horrible.”  The one thing that puzzles us the most about this sprawling statement is this: Donald Trump’s late uncle, Dr. John Trump, was indeed a renowned professor at MIT, and among his many notable contributions to science were developing methods for treating cancer through radiation and studying how to radiate deep tumors without harming nearby healthy tissue. But what did he reveal to his nephew about “nuclear” 35 years ago that it would have been surprising for anyone to think of?

Ex Output:
A tweet reproduces a 90-second long sentence from a Donald Trump speech.


Ex Input:
"SInce the test drug is in the very early stages of development, this criterion is technically not applicable. However, the present treatment regimen of an interferon and ribavirin costs thousands of dollars monthly for 6-12 months and it is likely that any newer antivirals will be additive and not replacements. A comment on the potential for significant additional costs would have been desirable. The story got a little carried away here. It said participants treated with the experimental drug had a ""dramatic"" reduction in viral load. While this may be true, it would have been helpful to point out, as the HealthDay story did, that the study lasted only a few days. We don’t know whether this benefit can be maintained over a longer period of time, especially considering that the hepatitis C virus has proven to be quite capable of developing resistance to antivirals over time. The story says study participants who took the drug exhibited ""few side effects."" But what were those side effects and how serious were they? The story doesn’t say. While the implication here is that the drug seems to be safe — a conclusion that we can’t really draw based on a small, early phase test — the story does include a cautionary quote from an expert about the need for additional testing to demonstrate safety. It also noted that patients taking this drug might still need to be treated with interferon, which many individuals can’t tolerate because of side effects. A close one, but we’ll call it satisfactory. This story includes appropriate caveats about the early nature of this research and includes a restraining quote from an expert who warns that the drug might not make it out of phase II tests. Unlike the competing HealthDay piece, this story resisted getting too worked up about the other experimental drugs for hepatitis-C that are closer to potential FDA approval. This story does not exaggerate the prevalence or severity of hepatitis C. According to disclosure statements from a 2008 CME program, Dr. Bruce Bacon, an expert source for this story, received research funding from Bristol Myers Squibb, which is developing the experimental drug being discussed. He also is a consultant to drug companies developing competing drugs for hepatitis C. To avoid the appearance of a conflict of interest it is desirable to identify relationships such as these clearly. This story fails to do so. The story compares the new drug with intravenously administered peg-interferon and ribavirin — the current standard of care for hepatitis C. The story called the research on BMS-790052 ""preliminary"" and made it clear that the drug was not close to approval. It also was more cautious than the competing HealthDay piece in its description of two other antiviral drugs that are nearing FDA approval. The story notes that there are many other drugs being developed to treat hepatitis C. It explained that a potentially novel advantage of the new compound is that it seems to be effective against all genotypes. We can’t be sure whether this story relied on a news release."

Ex Output:

Experimental Drug May Treat Hepatitis C